We have developed proprietary stabilizing chemistries to improve the robustness of siRNA sequences, together with advanced delivery systems that enable us to specifically target relevant cell types. This results in potent and highly specific product candidates.
Find out more about our investment case, share price, corporate governance and related information. Download our latest reports and announcements.
Silence has been a pioneer in the RNAi field for over 18 years. Through the efforts of our skilled researchers and scientists, we have established an innovative platform with broad intellectual property protection. Using our RNAi-directed platform technologies, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. We are currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron loading anemias and complement-mediated disorders.